425 related articles for article (PubMed ID: 27459733)
1. Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection.
Bunnell KL; Vibhakar S; Glowacki RC; Gallagher MA; Osei AM; Huhn G
Pharmacotherapy; 2016 Sep; 36(9):e148-53. PubMed ID: 27459733
[TBL] [Abstract][Full Text] [Related]
2. Incidence of Acute Kidney Injury in Patients Coinfected with HIV and Hepatitis C Virus Receiving Tenofovir Disoproxil Fumarate and Ledipasvir/Sofosbuvir in a Real-World, Urban, Ryan White Clinic.
Michal JL; Rab S; Patel M; Kyle AW; Miller LS; Easley KA; Kalapila AG
AIDS Res Hum Retroviruses; 2018 Aug; 34(8):690-698. PubMed ID: 29766745
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice.
Bhattacharya D; Belperio PS; Shahoumian TA; Loomis TP; Goetz MB; Mole LA; Backus LI
Clin Infect Dis; 2017 Jun; 64(12):1711-1720. PubMed ID: 28199525
[TBL] [Abstract][Full Text] [Related]
4. HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
Huhn GD; Ramgopal M; Jain MK; Hinestrosa F; Asmuth DM; Slim J; Goldstein D; Applin S; Ryu JH; Jiang S; Cox S; Das M; Nguyen-Cleary T; Piontkowsky D; Guyer B; Rossaro L; Haubrich RH
PLoS One; 2020; 15(1):e0224875. PubMed ID: 31995556
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study).
Rosenthal E; Fougerou-Leurent C; Renault A; Carrieri MP; Marcellin F; Garraffo R; Teicher E; Aumaitre H; Lacombe K; Bailly F; Billaud E; Chevaliez S; Dominguez S; Valantin MA; Reynes J; Naqvi A; Cotte L; Metivier S; Leroy V; Dupon M; Allegre T; De Truchis P; Jeantils V; Chas J; Salmon-Ceron D; Morlat P; Neau D; Perré P; Piroth L; Pol S; Bourlière M; Pageaux GP; Alric L; Zucman D; Girard PM; Poizot-Martin I; Yazdanpanah Y; Raffi F; Pabic EL; Tual C; Pailhé A; Amri I; Bellissant E; Molina JM;
HIV Med; 2018 Mar; 19(3):227-237. PubMed ID: 29214737
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus treatment response to ledipasvir/sofosbuvir among patients coinfected with HIV and HCV: Real world data in a black population.
Banga J; Nizami S; Slim J; Nagarakanti S; Portilla M; Swaminathan S
Medicine (Baltimore); 2020 Mar; 99(11):e19140. PubMed ID: 32176039
[TBL] [Abstract][Full Text] [Related]
7. Glomerular filtration rate change during chronic hepatitis C treatment with Sofosbuvir/Ledipasvir in HCV/HIV Coinfected patients treated with Tenofovir and a boosted protease inhibitor: an observational prospective study.
Soeiro CASP; Gonçalves CAM; Marques MSC; Méndez MJV; Tavares APRA; Horta AMLMFCA; Sarmento-Castro RMDR
BMC Infect Dis; 2018 Aug; 18(1):364. PubMed ID: 30075765
[TBL] [Abstract][Full Text] [Related]
8. Ledipasvir and tenofovir drug interaction in human immunodeficiency virus-hepatitis C virus coinfected patients: Impact on tenofovir trough concentrations and renal safety.
Solas C; Bregigeon S; Faucher-Zaegel O; Quaranta S; Obry-Roguet V; Tamalet C; Lacarelle B; Poizot-Martin I
Br J Clin Pharmacol; 2018 Feb; 84(2):404-409. PubMed ID: 29028125
[TBL] [Abstract][Full Text] [Related]
9. Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection.
Liu CH; Sun HY; Liu CJ; Sheng WH; Hsieh SM; Lo YC; Liu WC; Su TH; Yang HC; Hong CM; Tseng TC; Chen PJ; Chen DS; Hung CC; Kao JH
Aliment Pharmacol Ther; 2018 Jun; 47(12):1690-1698. PubMed ID: 29665069
[TBL] [Abstract][Full Text] [Related]
10. Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C.
Fazel Y; Lam B; Golabi P; Younossi Z
Expert Opin Drug Saf; 2015 Aug; 14(8):1317-26. PubMed ID: 26043900
[TBL] [Abstract][Full Text] [Related]
11. Increased tenofovir monoester concentrations in patients receiving tenofovir disoproxil fumarate with ledipasvir/sofosbuvir.
Brooks KM; Castillo-Mancilla JR; Blum J; Huntley R; MaWhinney S; Alexander K; Kerr BJ; Ellison L; Bushman LR; MacBrayne CE; Anderson PL; Kiser JJ
J Antimicrob Chemother; 2019 Aug; 74(8):2360-2364. PubMed ID: 31081036
[TBL] [Abstract][Full Text] [Related]
12. The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study.
Younossi ZM; Stepanova M; Pol S; Bronowicki JP; Carrieri MP; Bourlière M
Liver Int; 2016 Jan; 36(1):42-8. PubMed ID: 26059860
[TBL] [Abstract][Full Text] [Related]
13. Serial changes in renal indices in chronic HCV patients with and without HIV co-infection receiving sofosbuvir and tenofovir-based therapies.
Abdel Alem S; El Garhy N; El Khateeb E; Khalil M; Cordie A; Elsharkawy A; Fouad R; Esmat G; Abdelbary MS
Trans R Soc Trop Med Hyg; 2023 Apr; 117(4):285-296. PubMed ID: 36397681
[TBL] [Abstract][Full Text] [Related]
14. Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C.
Buggisch P; Vermehren J; Mauss S; Günther R; Schott E; Pathil A; Boeker K; Zimmermann T; Teuber G; Vornkahl HP; Simon KG; Niederau C; Wedemeyer H; Zeuzem S
J Hepatol; 2018 Apr; 68(4):663-671. PubMed ID: 29133244
[TBL] [Abstract][Full Text] [Related]
15. Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct-acting antivirals and antiretroviral therapy.
Liu CH; Sun HY; Hsieh SM; Liu WC; Sheng WH; Liu CJ; Su TH; Tseng TC; Chen PJ; Hung CC; Kao JH
J Viral Hepat; 2021 Jun; 28(6):887-896. PubMed ID: 33759290
[TBL] [Abstract][Full Text] [Related]
16. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544
[TBL] [Abstract][Full Text] [Related]
17. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis.
Reddy KR; Bourlière M; Sulkowski M; Omata M; Zeuzem S; Feld JJ; Lawitz E; Marcellin P; Welzel TM; Hyland R; Ding X; Yang J; Knox S; Pang P; Dvory-Sobol H; Subramanian GM; Symonds W; McHutchison JG; Mangia A; Gane E; Mizokami M; Pol S; Afdhal N
Hepatology; 2015 Jul; 62(1):79-86. PubMed ID: 25846144
[TBL] [Abstract][Full Text] [Related]
18. Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study.
Liou BH; Sun HY; Yang CJ; Syue LS; Lee YL; Tang HJ; Tsai HC; Lin CY; Chen TC; Lee CY; Huang SH; Liu CW; Lu PL; Lin SP; Wang NC; Cheng A; Ko WC; Cheng SH; Hung CC;
Infect Dis Ther; 2021 Jun; 10(2):827-838. PubMed ID: 33733316
[TBL] [Abstract][Full Text] [Related]
19. 12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.
Luetkemeyer AF; McDonald C; Ramgopal M; Noviello S; Bhore R; Ackerman P
Clin Infect Dis; 2016 Jun; 62(12):1489-96. PubMed ID: 27025835
[TBL] [Abstract][Full Text] [Related]
20. Lack of clinically important PK interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide.
Custodio JM; Chuck SK; Chu H; Cao H; Ma G; Flaherty J; Ling J; Kearney BP
Pharmacol Res Perspect; 2017 Oct; 5(5):. PubMed ID: 28971607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
